ArticleJournal of microbiology and biotechnology2026
6-Shogaol from Banxia Xiexin Tang: A Potent Regulator of Th17/Treg Balance to Protect Against CPT-11-Induced Intestinal Mucosal Damage.
Article in Journal of microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cancer cachexia as an immunometabolic syndrome: targeting the immunometabolic interface with traditional Chinese Medicine monomers and formulas.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irinotecan (CPT-11)-induced intestinal mucosal injury is a common complication of chemotherapy, significantly affecting gastrointestinal health. This study aimed to explore the potential therapeutic effects of 6-shogaol, a key component of Banxia Xiexin Tang (BXXXT), on regulating the T helper 17 cells (Th17)/regulatory T cells (Treg) balance to alleviate CPT-11-induced intestinal mucosal injury in rats. Rats were treated with CPT-11 to induce intestinal mucosal injury and subsequently exposed to 6-shogaol or BXXXT. Body weight, disease activity index (DAI), and histopathological changes in the small intestine were assessed. Biomarkers of intestinal injury, including D-lactic acid, diamine oxidase (DAO) and endotoxin, were measured. Enzyme-linked immunosorbent assay and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were performed to evaluate inflammatory cytokine levels in serum and small intestine tissues. Through flow cytometry, RT-qPCR and Western blot, the Th17/Treg balance was examined. Both 6-shogaol and BXXXT significantly alleviated CPT-11-induced intestinal mucosal injury, as demonstrated by increased body weight, reduced DAI, and improved histopathological results. Both treatments decreased the levels of intestinal damage-related biomarkers (D-lactic acid, DAO, and endotoxin) and suppressed the inflammatory response. Furthermore, 6-shogaol treatment restored the Th17/Treg balance by decreasing the proportion of Th17 cells and increasing the number of Treg cells. Collectively, 6-shogaol, a major component of Banxia Xiexin Tang, effectively regulates the Th17/Treg balance and attenuates CPT-11-induced intestinal mucosal injury in rats, signifying that 6-shogaol holds therapeutic potential for preventing and curing chemotherapy-induced gastrointestinal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.